Intro - 00:00:01: Welcome to The Biotech Startups Podcast by Excedr. Join us as we speak with first-time founders, serial entrepreneurs, and experienced investors about the challenges and triumphs of running a biotech startup from pre-seed to IPO with your host, Jon Chee. In our last episode, we spoke with Kate about balancing law school with full-time work, the challenges scientists face entering the legal profession, and how her firm's collaborative culture leverages the expertise of former scientists. If you missed it, be sure to go back and listen to part two. In part three, we continue our conversation with Kate as she shares invaluable advice on safeguarding innovations and the fundamentals of IP strategy. We'll also discuss the importance of aligning scientific advancements with proactive patent strategies, the critical timing for startups to address IP concerns, and the nuances of international patenting. From provisional applications to navigating resource constraints, Kate offers practical tips for founders looking to strengthen their IP foundations and attract investors.
Jon - 00:01:19: You talk about having a breadth of exposure to industries and just really kind of learning to take the best of different disciplines and all of that. When a company, like let's say a biotech company is now. Approaching, you know, they're like, okay, we're going to form this company. We need to actually start taking like intellectual property seriously and get, get this, you know, done right. From all these learnings, and you don't need to distill it down into like a, you know, one kind of takeaway, but like, what are like... Some just like foundational elements for a biotech company to know and follow through on when it comes to protecting their IP.
Kate - 00:01:58: Yeah, I think an important thing. For a smaller company. You don't always think about. It's just kind of, you build a foundation scientifically. And you want to make sure that your patents reflect that great foundation. I think a lot of people, startups, right? You're, everybody's short on cash. You're always looking for new investment. But we advise like spend the money on IP because you might not know it then when you're just starting out and depending on who's advising you, like this provisional application or this first application you file, this is the basis for your company and you want to put your best foot forward. You want to make sure that it's complete. And, you know, this is the priority for 20 years. This, this is what you're going to have for 20 years. You, at a certain point, you can't add to it. And so you want to make sure it's as good as possible. And I think some people like, well, we'll just get it on file and improve it later. It's like, you can do that, but it's important to spend the money now on a good patent attorney or just a good application to make sure that your foundation is solid. Because if you're. Building and not on like you know to use some construction like that keystone and you're you don't want it all to topple or kind of fall over or not be as strong when investors come knocking or when you want to sell your company or something. And so I think so many people are like, well, we'll just get something on file. It can be kind of narrow and we won't pay that much money for it. It's like, pay the money up front, get a good application on file because it will repay you in the long run. It's a small expense to pay in the grand scheme of things if you're looking for millions of dollars later down the road. So I was trying to explain that to startups. And I think they get it, but then they also get pressure from, especially some that go IPO really early. They're like, but our investors. I was like, well, your investors are going to want to see a good IP portfolio. So, do it the right way.
Jon - 00:04:05: And I guess, you know, in terms of like chronologically, I'll just use it like an example. If there's like... You know, some founders that are looking at tech transfer out of university and they're looking to incorporate the company. Is that like as early as you want to be like thinking about the IP portfolio or IP protections and strategy that early? Or at what point in time in a company's like stage of growth, is it like pivotal that you start really thinking long and hard and getting your IP taken care of, you know, completely and with a high bar?
Kate - 00:04:39: Yeah. I mean, in my experience, typically when I've seen spin-outs come from a university or the smaller startups, it's usually based on... IP from the university. Like they did it while they were in a lab and they were like, all right, now I'm going to. Spin out this company. And so I think even, you know, at the university stage, it is worth. If you and the university think it's something commercially... It's worth investing the money up front because... I think the IP strategy. It might morph over time and then... Then you see where you're going. But to me, it seems like companies should be, their science and their IP should go hand in hand. Like if you're, yes, they should be running in parallel. And if your science morphs a little bit, think about filing a new application because especially as a university, when you're in the university or as a startup and you're still going to conferences and trying to get the word out and presenting materials to investors. You have to be careful what you say. So there's also the part about maybe you're not filing a new application on it, but we tell companies, try to train them, like, let me see your slide deck before you go out. Do not. Somebody's like, oh, we're going to talk to so-and-so. This is our slide deck. And companies will send it to their IP attorney. And I was like, do you really have to say this? It's not in an application. Is it central to your messaging? Like, can you take it out? Because we're not ready to file on it yet. But if you talk about it, then we can't file on it. So there's a give and take, even if, you know, so your IP portfolio should still be front and center, even if you're going to talk to investors. Maybe you're not filing on it, but when is the right time to reveal, you know, this new development or something?
Jon - 00:06:31: And is that because when, in essence, when you do talk about it, it puts it in the public domain?
Kate - 00:06:37: Right. Especially if you've made a slide deck, right? If you've made a slide deck and someone, and you've sent it to somebody, it's not confidential anymore. If you have a CDA in place, it's different. But sometimes you're going to investors. And I know, you know, if you're going to JP Morgan or some places, they don't want a CDA because they don't want to be. Contaminated. By your confidential information. You know, you want to make sure that what you're giving them is not confidential information. And so before some of these bigger conferences were like, Let me see what you have. You know, can you run it by us? And I mean, I think it's just a good practice to get into because you don't want to accidental disclosures.
Jon - 00:07:18: That's a big oopsies. You don't want to. It sounds simple, but it's just like that could be monumental. Like-
Kate - 00:07:25: Yes.
Jon - 00:07:27: Incredible like asymmetric downside, like, if this is like the secret sauce, here's like oh, well this is now out there.
Kate - 00:07:34: Yeah, you're like, wait, but I talked about this at this conference, you're like, all right. Okay. How do we fix it? Back to the flexibility. You're like, all right. You're like, now that it's there, let's not dwell on that. What can we do? What can we do to fix it?
Jon - 00:07:50: Yeah. And I think the timing is perfect. You know, it's, you know, we, JPM is like, you know, coming up in January. So it's like, for any of the listeners out there, please take it.
Kate - 00:07:58: Exactly.
Jon - 00:07:58: Like, think about it. Just think, just think about this. And so when you kick off the process of, you know, okay, you're like, I'm going to get ahead of this. I'm going to start setting up these foundational, you know, kind of fencing things off. How long is the process to actually get? Get like a solid like patent, you know, and can you talk a little bit about the phases of that? Like, what is it? What is the absolute time span to get that done? And kind of what are the phases of that?
Kate - 00:08:26: Yeah, it takes a long time, at least in the biotech world, which is kind of okay because most of the times we're not in a hurry. Like we have time to kill while things are in development. You know, initially what... You can file what's called a provisional application and it kind of puts your stake in the ground. Like, this is my idea. This is when I thought of it. And so you can file a provisional. Which doesn't have to be, super complete. It doesn't have to have everything. Possible in it. It gives you one year, to collect more data. Or, you know, if you have four possible lead products, maybe within a year, you could narrow it to two. And then you can focus on those two, maybe compared to all four. So you put your stake in the sand when you file a provisional application, and then you have a year to roll new data or anything else into it. And so... If you say on January 1st, 2025, I'm filing this application, you have until January 1st, 2026 to get anything new in it. And then when you file a regular application or we call it patent cooperation treaty application, a PCT, which helps you kind of put your stake in internationally, your application has to be complete. There's no more additions. Like that is it. So you wanted to make sure by that one year deadline, you have everything in it that you're willing to talk about and disclose. And from there, if you file the U.S. application at the same time, it can take four to six years to get an application allowed. It's a minimum probably two years at the patent office to even start examination. There's so many patents being filed and not enough examiners that it takes a long time to even start.
Jon - 00:10:22: That is wild. That is actually wild. Well, one, let's get more staff in the patent office. That would help because that's a very long time.
Kate - 00:10:29: Yeah.
Jon - 00:10:30: I guess two follow-up questions to that. Do you recommend, or it doesn't have to be a recommendation. Do people go out and get global protections like out the gate? Or should you just start like, hey, we're a US-based company. Let's focus on the US IP protections now. We cross the international bridge later. Or do you need to set up international foundations like early to?
Kate - 00:10:53: You have to set them up pretty early. So I said you have the provisional and that one year date you have to file what's called like the PCT or the US. The PCT application then gives you like another year and a half and then you have to file. Internationally. So you kind of have to know at the beginning if you want to go international. So you have to have that in the back of your mind. And it depends on how broadly, but, you know, typically you want to file in Europe at least. You know, Europe, Japan, and China are a lot of the major markets. And they can be expensive, but that's another thing you need to plan for, unless you know that your market is really only the U.S., but, you know, kind of at a minimum, we always suggest U.S. and Europe, because that's where most of the drug companies are, and most of your population and your market probably is. It's a very narrow global outlook, but it's the reality of life sciences, at least.
Jon - 00:11:51: I always try to think about like working backwards and just like, you got to like really like kind of like try your best to like look into this like crystal ball. And just like work backwards. Cause like, that is not a surprise that you want to have later where you're just like, Well, now we've got to wait four years.
Kate - 00:12:09: Yeah.
Jon - 00:12:10: And oh, oops, didn't do international. That might throw on up X more years. Anyway, so I'm just like thinking about for anyone, I'm trying to empathize with like a founder who's like just embarking on this. It's like, you know, you got to think as far ahead as you can.
Kate - 00:12:24: Yeah, it's like a good five-year plan.
Jon - 00:12:27: Yeah.
Kate - 00:12:27: It's like one year there's a rush to get all that data in and then kind of waiting for five years, which sometimes can be good and bad because, especially I think for a startup. You don't necessarily know which way the science is going to develop. And so it gives you a little bit of time. Try to put a positive spin on it. It gives you a little bit of time to get some more data and kind of focus in on what's important. And, you know, maybe you go after the first commercial thing and then you can patent some other stuff later. And so it does help in that. It's not so fast that you... Get a patent on something that in two years becomes irrelevant because your ideas have shifted. So it gives you a good four-year runway, probably, to think about what you want to do.
Jon - 00:13:16: Yeah. And at what point in that kind of like. Process and journey are investors like, oh, this is like, this can be the bedrock. This is investable. Is it when the patent is like issued, like four years later, or like can provisionals get you a long way when it comes to raising capital?
Kate - 00:13:36: Usually a provisional is not quite the sale because people want to know that it is patentable potentially, but it can be. It depends on who your investors are and kind of what you're selling. Like a lot of investors, especially ones that invest in biotech specifically, do their due diligence and will read the application and say, We think this is good technology, and some people don't go that deep and say they just want to see an issued patent. So sometimes it depends on who you're investing in. Typically, having an issued patent is more valuable.
Jon - 00:14:12: Absolutely.
Kate - 00:14:12: Having a provisional will say, we know what we're doing. We're on our path. We're early stage, so.
Jon - 00:14:18: Something that stood out to me is if it's a lifestyle-specific investor, they kind of know exactly what they're looking at. And so they can probably be more flexible versus, you know. Someone who might be a more generalist investor. They don't really know what I'm looking at, but I just want to see the patent.
Kate - 00:14:36: Right, they just want to see that it's there and then you have some claims, whereas the biotech guys are going to look and analyze your claims. Then you can say, this is our five-year plan. This is what we had planned for this. They get it.
Jon - 00:14:52: Absolutely. And for companies that are, you know, if you're bifurcating like the sciences into either like kind of platform companies or specific, you know, kind of like. Candidates that they're trying to get all the way to the end line is does the ip strategy differ. For the company kind of strategy like that? Or does one approach it the same way?
Kate - 00:15:14: I think we tend to approach it the same way. I do have companies with platform technology. And so to the extent that the platform is patentable, sometimes platforms are harder to get because you want to get... Broad protection, but a lot of patent offices will say, you want broad protection, but you only showed me two examples, right? You can't. Show everything because that costs a lot of money, but you think that it's broadly patentable. And you can show it, it just takes more time. And so sometimes you try to patent the platform. The way the patent system works, at least, is you can file a continuation or a divisional. So you can be prosecuting the same family of applications at the same time, but with different subject matter. So if I have an investor who might be interested in InventionY. I could file a divisional or continuation, whichever is appropriate. And just go after invention Y and say, look, investor, I have a patent specific for what you're doing. Let's talk. And so there's a lot of strategies because then you can license off the pieces individually. You're like, maybe that investor is not going to do this disease, but they'll do this disease, or they want this part of the platform for what they're doing. So sometimes it's good to have multiple prongs going so that then you can license them off at the same time. But typically, you still want to get that platform protection so that you've got everything covered if possible.
Jon - 00:16:43: And I guess a follow-up question to that is that, do you see that the patent office is just making it harder to- Is it getting more difficult to get those broad platform protections? And I think there's narrowing it down.
Kate - 00:16:57: Is getting harder to get platform protections. They're slowly kind of making case law new rules that kind of for the support requirements, you know, back in the old days, we'll use antibodies as an example because I do a lot of that, right? You could get... An antibody that binds a protein X. And it would be very generic. It wouldn't have to have a sequence and you would cover anybody else who wanted to get an antibody to do that. And now... You have to have an antibody with a sequence. So now you have to have, it's very narrow, your antibody. Has to be a specific sequence. There's not a lot of variability that you can get in there. And so. Gone are the days where you could get in. Broad antibody patent. And now you get the specific sequence and maybe a little bit of variability if you've shown it, right? If you say, well, I know I can change these residues and it doesn't matter. Then the patent office will let you have it. They're gradually narrowing down what it takes to... Support. A broad claim there, like, We don't believe that this would work for everything. And so you have to have a good reason why it would work for everything. And even if you have a good reason, they don't care sometimes. It's like, I'm going to get some nasty calls from nasty grams for some examiners.
Jon - 00:18:15: Yeah. And I- Question a follow up question to that is when they gave. Broad protection. Do those, protection still, like, even though they've changed their view now. Are those broad general patents still enforceable? Or are they like, do they go back and say, actually, that was too broad. We now need to narrow that down and you don't get all the benefits of that super broad patent.
Kate - 00:18:41: The patent office doesn't do it. Once they issue something, they're like, we're done with this.
Jon - 00:18:47: We have a thousand more.
Kate - 00:18:49: Right, exactly. I got other things to do. It's like, we're out. So it's up to, the courts. And so a lot of it, people don't necessarily want to bring it up. Maybe so if you had that broad antibody claim and maybe now you saw one, a lot of those are expiring. Like you have 20 year term from when it's filed. So a lot of those are expiring now. But even then, the way the new case law is, it makes it a little risky if you want to enforce it against somebody. Because if you say you're infringing my super broad antibody claim, then the person that has that antibody will come back and say, well, that claim is invalid now. And so that's where it would get more into the court system as opposed to the patent office. The patent office is like, I'm out of there, but someone else can take care of it.
Jon - 00:19:37: And that's like a really interesting like wrinkle to it. Because I'm going to imagine as you're going in, like thinking about this strategy, you kind of have to forecast it a little bit. It's like if we go too broad here, it's like, yeah, on paper, it sounds great. But in practice, we might get smoked because someone might just say like this is too, this is onerous or it's like too broad.
Kate - 00:19:57: Right.
Jon - 00:19:58: And you're just like, well, why didn't we just not do it so broad in the beginning? Maybe we can actually dial it in a little bit, whereas actually it will have actual legs in the chord system.
Kate - 00:20:09: Right. And so that is a strategy, especially if you're getting close to having a product or something. You're like, is this the patent we want or do we want something that is narrow and tight and that is, you know, really. Hopefully. Not challengeable in a court system by somebody. But yes, there is a risk that when you get broad patent claims. That if somebody wants to do it, they'll challenge you on it and it might go down. So it always seems like a greater, you're like, look at what broad claim I got.
Jon - 00:20:40: Yeah, I got all of it. It's kind of like I was talking to our chief legal, we're talking about like CDAs and confidentiality. It's like, you have to be very specific and mark what's confidential. And like, in order for it to like, fall within the purview of like the CDA. But if you just like, when we tell people like, yeah, that little like disclaimer at the bottom of your email, it's like, not enough. Like you have to mark, like, just don't, don't like, you know, for any of the founders out there, it's like, that little email footer is not enough. You need to mark this and like, be very specific. And like, and also it's like, if you claim everything is confidential, nothing is confidential.
Kate - 00:21:19: Right, exactly.
Jon - 00:21:21: So it's kind of like too broad to the point where it's just like ineffective.
Kate - 00:21:24: Yes.
Jon - 00:21:25: And something that stood out too, that you're talking about how some investors will want like pieces, like kind of like the discrete, you know, piece of IP that for whatever modality or indication that they're most interested in. I think that's really valuable for founders to kind of contemplate because I know the podcast episode with Neela Patel, when she was running Good Therapeutics. Did exactly that. Like their platform had like a piece of IP that they just sold to Roche like specifically. And they knew that upfront. They like kind of planned the IP strategy along with the investors too. The investors were like. Yeah, like this piece of IP, like let's get an easy, like not an easy win, but like, let's get a win here. We know exactly who a potential buyer is going to be. And you can notch that win, get some cashflow from it and continue on. And you still have the broader platform. And because I think right now. There's a lot of, you know, writing and talk about how the hell can we like finance, like the life sciences.
Kate - 00:22:30: Yeah.
Jon - 00:22:31: Um, and. I think what people are realizing, you have to like think strategically and creatively about this. And these are kind of like an IP specific, like I think is like creative. It's like work with your investor up front. It's like, hey, like here's kind of like an opportunity for us to monetize this without like giving the whole platform away. And how we can like fund business. Or like, you know, you were talking about like the potential to like license different aspects, but like keep some within. So I think. Those strategies are really interesting to me.
Kate - 00:23:04: Yeah, it's a great way to, because especially as a small biotech and even as a bigger, a large biotech, you have to focus at some point. You're like, you have a lot of great ideas, but at some point you have to pick the ones that. Are the most important. And I know that's hard. Like it's hard to, you know, it's like, it's your baby, which child do you like? I don't need that one.
Jon - 00:23:25: Yeah, yeah, yeah. Exactly.
Kate - 00:23:25: But you're like, but if you give it to a good home, it'll be fine. And so, yeah, I think it's, it's hard sometimes for people to let go, but if they can see the benefits of it right now, the technology is going to be developed and hopefully it gets to market and we'll help people. And now we have cash to invest back in programs. Maybe we want to take forward. And so you can, you know, get farther down the line with your own stuff that maybe eventually you end up licensing off, but you need the money to get your proof of concept on or something. So, yeah.
Jon - 00:23:57: And I think you mentioned before, like, you know, it is important to get ahead of this, but with, you know, companies, you know, having obviously finite time and resources, you might have to pick some battles and not take some battles. If someone is trying to do this effectively with whatever budget that is afforded to them, what are some like things that like you should absolutely not forego when it comes to implementing an IP strategy? And then maybe what are like the type kind of things that can be more step two, step three? Like, what are the kind of the core things you need to get done to make sure that you're in decent shape?
Kate - 00:24:33: Yeah, I think that goes, again, to laying the solid foundation. I think you lay the solid foundation. And then sometimes early on, when you do have cash, you might say, all right, we're going to go into a lot of these countries. Maybe you're going to go into 10 countries and you've got all the kind of major markets plus some softer markets. And then maybe things are getting a little tighter or things develop however they are. And it's okay to... Only keep those major markets, right? A good way to save some money because each country requires. Or a lot of them at some point require annuities. Like you have to pay to just have the patent sitting there, not doing anything if it hasn't even been examined. And so sometimes that's a way to say, all right, well, maybe this country is not as important, but we'll keep the U.S., Europe, and like, again, like I said, Japan and China are kind of the major ones. Or before you do your foreign filing, try to think strategically, where are my markets? Do I need to go into all of these countries? Or, you know, the indication that I'm trying to treat isn't even in the Asian population. So why waste my money? So thinking strategically about where your market's going to be, or if you're, if you have manufacturing processes, maybe you also need to file in India because there's a lot of manufacturing there. So just kind of... Thinking beforehand what's important to you and what your strategy is going to be, can be saving cash up front and be like, all right, we're making these decisions now. And then... Later on. We can see where it develops. And then if you do have you know, you're lucky enough to get a lead candidate and take it forward and you get into phase one, you can file. More applications to some of these different, like the formulation or to the, ,the dosing and the treatment regimens that might not have been in the first application. So It's always data mining and being aware of what new things that can come out that can be patentable because then that extends your patent life for another five or ten years depending on how long it's been in development. So... You know, it's just being very mindful of what. What the science is telling you and not being afraid to, it's hard, but it's not being afraid to say, you know what, this is not important to us anymore. And we can't find anyone else to buy it. Like it's not working out how we thought, and we're just going to let it go. And so sometimes it's, it's a hard decision to make, but it's the right decision.
Jon - 00:27:06: Totally. Maybe it's because I'm based in San Francisco, but there's always like this. Notion of like fast break things kind of, you know, who needs a plan? Who needs a business plan? That's so old school. But like, every time I'm like, business plans are great. Like, is this type of stuff that you can avoid? Like a lot of like, you can be really, really like efficient with your, your finite resources and time. That's going to be incredibly impactful on your IP strategy and how you like actually execute on it.
Kate - 00:27:39: Yeah.
Jon - 00:27:40: Versus exactly like, oh, screw it. We're just going to like one, just like freestyle this. And it's like, oh, it's too late. And now I'm like four years behind. Or you just do too much upfront. And you're like, well, we actually didn't need all of this.
Kate - 00:27:53: Right.
Jon - 00:27:53: And now that's like money out the door and time out the door when you could have like narrowed it down a little bit for your exact needs.
Kate - 00:28:01: Yeah. A little streamlined. And I mean, and I'm sure investors like to see a plan, right? They like to know that you have a plan and a strategy. So even if it's 90% of a plan, it's still better than no plan.
Jon - 00:28:14: Better than no plan. Like, better than no plan.
Outro - 00:28:19: That's all for this episode of The Biotech Startups Podcast. We hope you enjoyed our discussion with Kate Neville. Tune in for part four of our conversation to learn more about her journey. If you enjoyed this episode, please subscribe, leave us a review and share it with your friends. Thanks for listening. And we look forward to having you join us again on The Biotech Startups Podcast for part four of Kate's story. The Biotech Startups Podcast is produced by Excedr. Don't want to miss an episode? Search for The Biotech Startups Podcast wherever you get your podcasts and click subscribe. Excedr provides research labs with equipment leases on founder-friendly terms to support paths to exceptional outcomes. To learn more, visit our website, www.excedr.com. On behalf of the team here at Excedr, thanks for listening. The Biotech Startups Podcast provides general insights into the life science sector through the experiences of its guests. The use of information on this podcast or materials linked from the podcast is at the user's own risk. The views expressed by the participants are their own and are not the views of Excedr or sponsors. No reference to any product, service or company in the podcast is an endorsement by Excedr or its guests.